Catalog | Name | Composition | Particle size | Specifications | Storage condition | Shelf life | Application | Description |
NZs-44 | Pt/VP@MLipo | Pt, verteporfin (VP), Lipo | 100-200 nm | 50 mg
100 mg | -4 ℃ | 6 months in sealed condition | Antitumor | Pt/VP@MLipo is biomimetic liposome nanomaterial composed of platinum nanoparticles, photosensitizer VP and mouse macrophage membrane. It is multifunctional, controllable and safe, and can be used for photochemotherapy of cancer. |
NZs-45 | Pt@Au-Ce6/Res-Lip | Pt, Au, chlorin e6 (Ce6), resveratrol (Res), liposome (Lip) | 70-120 nm | 50 mg
100 mg | -4 ℃ | 6 months in sealed condition | Antitumor | Pt@Au-Ce6/Res-Lip has efficient catalytic activity. It can decompose overexpressed hydrogen peroxide in the tumor microenvironment to produce large amounts of oxygen to enhance the effect of photodynamic therapy. Pt@Au-Ce6/Res-Lip is also highly targeted. Its gold nanoshell has near-infrared light responsiveness and can generate high heat under 808 nm laser irradiation to achieve photothermal therapy (PTT) at the lesion site while inducing the controlled release of the photosensitizer Ce6 and the chemotherapy drug Res. |
NZs-46 | BSA-IrO2 | bovine serum albumin (BSA), IrO2 | 20-50 nm | 50 mg
100 mg | -4 ℃ | 6 months in sealed condition | Anti-inflammatory and antitumor | BSA-IrO2 has extraordinary photothermal conversion efficiency, good photocatalytic activity, and a high X-ray absorption coefficient. It can achieve tumor phototherapy under near-infrared light irradiation, and simultaneously perform photoacoustic/thermal imaging and computed tomography to achieve precise diagnosis and treatment of tumors. It can also protect normal cells from H2O2-induced reactive oxygen pressure and inflammation. |
NZs-47 | Fmoc-Cys/Fe@Pc/ACF | fluorenylmethyloxycarbonyl (Fmoc), cysteine (Cys), Fe3+, zinc(II) phthalocyanine (ZnPc), acriflavine (ACF) | 200 nm | 50 mg
100 mg | -4 ℃ | 6 months in sealed condition | Antitumor | Fmoc-Cys/Fe@Pc/ACF are CAT-like photosensitizing nanozymes with a self-oxygen-supplying capability. Among them, the released Fe3+ could catalyze the transformation of H2O2 enriched in cancer cells to oxygen efficiently, thereby ameliorating the hypoxic condition and promoting the photosensitizing activity of the released ZnPc. |
NZs-48 | ICG@hMnOx | Indocyanine Green (ICG), hMnOx | 50-100 nm | 50 mg
100 mg | -4 ℃ | 6 months in sealed condition | Photothermal-boosted catalytic therapy of methicillin-resistant staphylococcus aureus (MRSA) infections | ICG@hMnOx has bacteriophage-spike morphology and hollow structure, and its surface is porous and rough. It can not only destroy biofilms through the photothermal effect, but also effectively amplify its catalytic activity under near-infrared light stimulation when it adheres to the bacterial surface, thus serving as a bacterial membrane-anchored reactive oxygen species generator. |
NZs-49 | Pt@BP nanosheets | Pt, black phosphorus (BP) | 500 nm | 50 mg
100 mg | -4 ℃ | 6 months in sealed condition | Antitumor | Pt@BP nanosheets combine the photodynamic activity of BP nanosheets and the CAT activity of Pt nanoparticles to achieve multi-modal tumor treatment and imaging. |
NZs-50 | rMGB | GOD, MnO2, BSA-Chlorine e6 (BSA-Ce6) | 100 nm | 50 mg
100 mg | -4 ℃ | 6 months in sealed condition | Intensive starvation and
photodynamic therapy for hypoxic tumors | rMGB integrates natural enzyme glucose oxidase (GOD) with nanozyme manganese dioxide (MnO2) by mutual promotion for maximizing the enzymatic activity of MnO2 and GOD. Under hypoxia environment, the rMGB could catalyze endogenous H2O2 and H+ to generate O2 in tumor site, providing O2 to GOD for cancer starvation therapy. Meanwhile, GOD provides a large amount of H+ which helps the MnO2 to further accelerate O2 generation for alleviating tumor hypoxia and enhance photodynamic therapy (PDT) efficacy. Moreover, rMGB could not only achieve the longcirculation effect and effective tumor accumulation but also avoid the systemic toxicity of GOD by reason for the GOD leakage and H2O2 generation. |
NZs-51 | CeO2@MMT | CeO2, MMT | 5 nm | 50 mg
100 mg | -4 ℃ | 6 months in sealed condition | Inflammatory
bowel disease therapy | CeO2@MMT nanozymes combine the CeO2 nanozyme with ROS elimination activity and the negatively-charged montmorillonite (MMT) to achieve the complementary advantages of each component. CeO2 nanoparticles grown in situ on MMT sheets confer ROS scavenging activity to the MMT sheets, while the MMT sheets significantly minimize the systemic absorption of CeO2 nanoparticles and thus reduce their potential nanotoxicity. In additon, CeO2@MMT nanozymes have high ROS scavenging activity and high stability in the digestive tract. |
NZs-52 | V2O5@pDA@MnO2 | V2O5, polydopamine (pDA), MnO2 | about 200 nm | 50 mg
100 mg | -4 ℃ | 6 months in sealed condition | Inflammation therapy | V2O5@pDA@MnO2 nanocomposite could serve as one multi-nanozyme model to mimic intracellular antioxidant defense procedure in which CAT, superoxide dismutase (SOD), glutathione peroxidase (GPx), etc. It exhibited excellent intracellular ROS removal ability to protect the body against oxidative stress, showing its potential application in inflammation therapy. |
NZs-53 | Mn3O4 nanozyme | Mn3O4 | 500 nm | 50 mg
100 mg | -4 ℃ | 6 months in sealed condition | Prevent
ROS-mediated neurological disorders. | Mn3O4 nanozyme functionally mimic three major antioxidant enzymes, namely CAT, SOD and GPx, and the multienzyme activity is size as well as morphologydependent. It can robustly rescue the cells from oxidative damage and thereby possess therapeutic potential to prevent ROS-mediated neurological disorders. |
NZs-54 | MOF-818 | MOF-818 | 200-400 nm | 50 mg
100 mg | -4 ℃ | 6 months in sealed condition | Chronic wound treatment | MOF-818 have high CAT and SOD activities, which can scavenge ROS at wound sites. In addition, they also have good biocompatibility. |
NZs-55 | Ultrasmall SnFe2O4 nanozyme | SnFe2O4 | 10-50 nm | 50 mg
100 mg | -4 ℃ | 6 months in sealed condition | Synergistic cancer therapy | Ultrasmall SnFe2O4 nanozyme has CAT-like activity and can react with hydrogen peroxide to generate oxygen to alleviate severe hypoxia in tumors. In addition, it also exhibits GPx-like activity, which can scavenge overexpressed glutathione (GSH) and weaken the antioxidant capacity of tumors. Under 808 nm laser irradiation, SnFe2O4 nanozyme can also produce photothermal therapy (PTT) and photodynamic therapy (PDT) efficacy. Combined with CT and magnetic resonance (MR) imaging functions, SnFe2O4 nanozyme can more accurately monitor the treatment process, showing great potential for synergistic therapeutic effects. |
NZs-56 | Cu5.4O USNPs | Cu5.4O | 200-400 nm | 50 mg
500 mg | -4 ℃ | 6 months in sealed condition | Treatment of ROS-related diseases | Ultrasmall copper based nanoparticles (Cu5.4O USNPs) have the distinctive advantages of the ultrasmall particle size, rapid renal clearance, high biocompatibility and broad reactive oxygen species (ROS) scavenging abilities. Cu5.4O USNPs simultaneously possessing CAT-, SOD-, and GPx-mimicking enzyme properties exhibit cytoprotective effects against ROS-mediated damage at extremely low dosage and significantly improve treatment outcomes in acute kidney injury, acute liver injury and wound healing. Meanwhile, the ultrasmall size of Cu5.4O USNPs enables rapid renal clearance of the nanomaterial, guaranteeing the biocompatibility. The protective effect and good biocompatibility of Cu5.4O USNPs will facilitate clinical treatment of ROS-related diseases and enable the development of next-generation nanozymes. |
NZs-57 | A-Pd@MoO3-x NH | Pd, MoO3-x | 100 nm | 50 mg | -4 ℃ | 6 months in sealed condition | Tumor-specific therapy | Utilizing the irregular shape characteristics of nano Pd, the A-Pd@MoO3-x NH nanozyme simultaneously exhibits CAT-like and oxidase-like activities. This can catalyze cascade enzymatic reactions to overcome the negative effects of tumor hypoxia caused by the accumulation of cytotoxic superoxide radicals in tumor microenvironment without any external stimuli. |
NZs-7 | 2D cobalt hydroxide oxide
nanosheets | Co | 50-70 nm | 50 mg
100 mg | -4 ℃ | 6 months in sealed condition | Inhibit inflammation | 2D cobalt hydroxide oxide nanosheets exhibit superior reactive oxygen species (ROS) scavenging properties and can protect cells from oxidative damage. |
NZs-21 | Ir-N5 SA | Ir, N | 50-100 nm | 50 mg
100 mg | -4 ℃ | 6 months in sealed condition | Antitumor | Ir-N5 SA is a single-atom nanozyme composed of a single iridium atom and five nitrogen atoms and has a variety of enzyme-like catalytic activities including CAT-like, peroxidase (POD)-like, oxidase-like and NADH-like oxidase (NOX) activities. |
NZs-22 | BiO2-x nanosheets | BiO2-x | 100-250 nm | 50 mg
100 mg | -4 ℃ | 6 months in sealed condition | Piezocatalytic, sonothermal, and enzymatic therapies | BiO2-x nanosheets exhibit CAT-like and POD-like activities. The oxygen vacancies generated in BiO2-x nanosheets are beneficial to the adsorption of H2O2 and increase the carrier density for the production of ROS. In addition, BiO2-x nanosheets also have excellent acoustic and thermal effects. |
NZs-23 | AuPtCo nanozymes | Au, Pt, Co | 100-200 nm | 50 mg
100 mg | -4 ℃ | 6 months in sealed condition | Glow-type chemilumines-cence bioanalysis | Taking advantage of the good charge transfer and synergistic effects between gold, platinum, and cobalt elements, AuPtCo nanozymes exhibit strong catalytic activity. AuPtCo nanozymes can catalyze the Chemiluminescence (CL) emission in a flash type after reacting with the substrate N-(4-Aminobutyl)-N-ethylisoluminol (ABEI) and the oxidant H2O2. |
NZs-24 | Fe3O4@Pt@E5 | Fe3O4, Pt, E5 | 10-50 nm | 50 mg
100 mg | -4 ℃ | 6 months in sealed condition | Acute myeloid leukemia treatment | Fe3O4@Pt@E5 exhibit CAT-like, POD-like and oxidase activities. It has uniform morphology and small size, and has good stability and biocompatibility. |
NZs-25 | Prussian Blue Nanozymes | Fe4[Fe(CN)6]3, KFe[Fe(CN)6] | about 200 nm | 50 mg
100 mg | -4 ℃ | 6 months in sealed condition | Antioxidant and anti-inflammatory materials, etc. | Prussian blue nanozymes can effectively scavenge ROS via multi-enzyme activities including POD-like activity, CAT-like activity and SOD-like activity. Prussian blue nanozymes can be used as new antioxidant and anti-inflammatory materials, and can also be used in the fields such as drug loading, photothermal therapy, inflammatory tissue imaging and construction of biosensor devices. |
NZs-26 | Fe3O4 nanozymes | Fe3O4 | 200 nm | 50 mg
100 mg | -4 ℃ | 6 months in sealed condition | Promote stroke
healing | Fe3O4 nanozymes exhibit triple enzyme-like activities including POD, CAT and SOD, thus potentially possessing the ability to regulate the ROS level. |
NZs-28 | CoMo hybrids | Co(OH)2, MoSx | 5 μm | 50 mg
100 mg | -4 ℃ | 6 months in sealed condition | Colorimetric detection | The CoMo hybrids exhibit triple enzyme-like activities including CAT-, POD- and oxidase-like activities. In addition, the CoMo hybrids is also reproducible, stable and reusable, that is, after 10-cycle uses, >90% mimic enzyme activity of the CoMo hybrids is still maintained. |
NZs-40 | RuO2 NPs | RuO2 | 5 nm | 50 mg
100 mg | -4 ℃ | 6 months in sealed condition | Prevention of acute kidney injury | RuO2 NPs catalytic properties mimic the activity of CAT, POD, SOD and GPx. In addition, RuO2 NPs show excellent antioxidant activity and low biological toxicity. And the nanozyme can be efficiently and rapidly absorbed by human embryonic kidney cells while significantly reducing ROS-induced apoptosis by eliminating excess ROS. |
NZs-43 | PEG/Ce-Bi@DMSN | CeO2, Bi2S3, dendritic mesoporous
silica nanoparticles (DMSN), PEG | 100 nm | 50 mg
100 mg | -4 ℃ | 6 months in sealed condition | Tumor nanocatalytic therapy | PEG/Ce-Bi@DMSN exhibit dual enzymemimic catalytic activities (i.e., CAT- and POD-mimic activities) under acidic conditions that can regulate the tumor microenvironment, that is, simultaneously elevate oxidative stress and relieve hypoxia. In addition, the nanozymes can effectively consume the overexpressed GSH through redox reaction. |